SYRE Form 4: CEO disposes 45,000 shares; holds 701,907 post-sale

Rhea-AI Filing Summary

Spyre Therapeutics (SYRE) reported insider activity: the Chief Executive Officer and Director sold 45,000 shares of common stock on 11/03/2025 under a Rule 10b5-1 trading plan adopted on June 20, 2025. The sales comprised 28,155 shares at a weighted average price of $23.13 (range $22.51–$23.50) and 16,845 shares at a weighted average price of $23.66 (range $23.51–$24.04). Following these transactions, the reporting person beneficially owns 701,907 shares, which includes 188,743 shares scheduled to vest in monthly installments over approximately one year, subject to continued service.

Insights

Securities law analyst

Routine Form 4 sale under a pre-set 10b5-1 plan; neutral impact.

The CEO of Spyre Therapeutics executed two market sales totaling 45,000 shares on 11/03/2025 pursuant to a Rule 10b5-1 plan adopted on June 20, 2025. Prices were reported as weighted averages of $23.13 and $23.66, with specified trading ranges.

Post-transaction beneficial ownership is 701,907 shares, which includes 188,743 time-based vesting shares. The filing lists standard price ranges and the undertaking to provide detailed trade breakdowns upon request.

Form 4 sales like this are administrative disclosures and, by themselves, typically do not alter the investment thesis. Actual market impact depends on broader trading volume and subsequent disclosures.

Insider Trade Summary

Net Seller: 45,000 shares ($1,049,778)

Net Sell 2 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 45,000 shs ($1.05M)

Type	Security	Shares	Price	Value
Sale	Common Stock	28,155	$23.13	$651K
Sale	Common Stock	16,845	$23.66	$399K

Holdings After Transaction: Common Stock — 718,752 shares (Direct)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.51 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		S(1)		28,155	D	$23.13(2)	718,752(3)	D
Common Stock	11/03/2025		S(1)		16,845	D	$23.66(4)	701,907(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.51 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report?

The CEO and Director sold a total of 45,000 SYRE common shares on 11/03/2025 under a Rule 10b5-1 plan.

At what prices were the SYRE shares sold in the Form 4?

Weighted average prices were $23.13 (range $22.51–$23.50) for 28,155 shares and $23.66 (range $23.51–$24.04) for 16,845 shares.

How many SYRE shares does the reporting person own after the sale?

Beneficial ownership after the transactions is 701,907 shares.

Was the SYRE sale under a Rule 10b5-1 trading plan?

Yes. The transactions were executed pursuant to a Rule 10b5-1 plan adopted on June 20, 2025.

Do the reported holdings include unvested shares or awards?

Yes. They include 188,743 shares that vest monthly over approximately one year, subject to continued service.

What transaction code appears in the SYRE Form 4?

Transaction code S indicates an open market or private sale of non-derivative securities.